Carla Kurkjian

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

Johanna C. Bendell, Carla Kurkjian, Jeffrey R. Infante et al. · Investigational New Drugs · 2015 · 115 citations

Pharmacy, Oncology, Pharmacology +8

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 93 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Geoffrey I. Shapiro, Patricia LoRusso, Eunice L. Kwak et al. · Investigational New Drugs · 2019 · 92 citations

Medicine, Oncology, Pharmacology +12

A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer

Shubham Pant, Suzanne F. Jones, Carla Kurkjian et al. · European Journal of Cancer · 2016 · 91 citations

Medicine, Oncology, Pharmacology +12

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors

Shubham Pant, Mansoor N. Saleh, Johanna C. Bendell et al. · Annals of Oncology · 2014 · 82 citations · Full text

Medicine, Oncology, Pharmacology +9